Head-To-Head Survey: Genetic Technologies (NASDAQ:GENE) and Vir Biotechnology (NASDAQ:VIR)

Vir Biotechnology (NASDAQ:VIR) and Genetic Technologies (NASDAQ:GENE) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

Volatility & Risk

Vir Biotechnology has a beta of 0.48, suggesting that its share price is 52% less volatile than the S&P 500. Comparatively, Genetic Technologies has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500.

Insider and Institutional Ownership

65.3% of Vir Biotechnology shares are held by institutional investors. Comparatively, 0.6% of Genetic Technologies shares are held by institutional investors. 15.6% of Vir Biotechnology shares are held by insiders. Comparatively, 6.5% of Genetic Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Vir Biotechnology and Genetic Technologies’ gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vir Biotechnology	$86.18 million	13.75	-$615.06 million	($4.01)	-2.16
Genetic Technologies	$8.49 million	0.46	-$7.91 million	N/A	N/A

Genetic Technologies has lower revenue, but higher earnings than Vir Biotechnology.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Vir Biotechnology and Genetic Technologies, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vir Biotechnology	0	3	3	0	2.50
Genetic Technologies	0	0	0	0	N/A

Vir Biotechnology currently has a consensus target price of $33.00, suggesting a potential upside of 280.62%. Given Vir Biotechnology’s higher possible upside, equities analysts clearly believe Vir Biotechnology is more favorable than Genetic Technologies.

Profitability

This table compares Vir Biotechnology and Genetic Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vir Biotechnology	-612.40%	-30.93%	-26.01%
Genetic Technologies	N/A	N/A	N/A

Summary

Vir Biotechnology beats Genetic Technologies on 6 of the 11 factors compared between the two stocks.

About Vir Biotechnology

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies. The company was incorporated in 2016 and is headquartered in San Francisco, California.

About Genetic Technologies

Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates through AffinityDNA, EasyDNA, and GeneType/Corporate segments. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, type 2 diabetes, pancreatic cancer, melanoma, and atrial fibrillation. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne for the development and commercialization of a novel colorectal cancer risk assessment test; and Memorial Sloan Kettering Cancer Center of New York and University of Cambridge, that assess the conflict among BRCA mutation carriers considering preventive surgery. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.